INTELLIA THERAPEUTICS

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 7 2025 13:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

15 6 2025 07:45:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 6 2025 13:01:00 提供 Nasdaq GlobeNewswire

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

18 5 2025 04:25:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

08 5 2025 04:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 5 2025 13:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

01 5 2025 04:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

07 4 2025 06:45:27 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 4 2025 08:02:20 提供 NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 4 2025 13:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

03 4 2025 04:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

02 4 2025 06:45:01 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

01 4 2025 06:45:33 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

31 3 2025 06:45:05 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

28 3 2025 08:04:59 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

27 3 2025 07:27:38 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

26 3 2025 09:26:53 提供 NetDania Notify

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

26 3 2025 04:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 3 2025 13:01:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 3 2025 06:46:52 提供 NetDania Notify